NY Times
MARCH 4, 2021
Interim results from clinical trials suggested that Covaxin could be safe and effective, potentially removing one hurdle to New Delhi’s ambitious campaign to inoculate a vast population.
pharmaphorum
MARCH 4, 2021
Radiologists in Europe could soon have help keeping children calm as they have MRI scans from Disney favourites like Micky Mouse, Winnie the Pooh and the Little Mermaid. Healthcare tech company Philips has teamed up with Walt Disney Corp to develop custom ambient animations – featuring some of the most-lived characters from Disney, Marvel and Star Wars shows – that can be played to children during the procedure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
MARCH 3, 2021
The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic. So what have been the learnings from the trial â and how could they be applied to vaccine development in the future?
Pharma Marketing Network
MARCH 1, 2021
[link]. Blockchain technology has become an increasing tool for life science organizations. How is this technology being implemented, and what value does it offer? Join Darshan Kulkarni as he talks with guest Jim Nasr about the function of blockchain, and how distributed ledger technologies such as blockchain are making an impact on healthcare. The post DarshanTalks: Blockchain & Information Technology</br> – March 1, 2021 appeared first on Pharma Marketing Network.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NY Times
MARCH 4, 2021
Johnson & Johnson’s one-shot vaccine is allowing states to rethink distribution, even as health officials and experts worry some will view it as inferior.
pharmaphorum
MARCH 3, 2021
Rare disease families need to stand up and be counted if they want things to change said mum and advocate Christine Waggoner. She spoke to pharmaphorum as part of our Patients Insights series. Like many “rare disease mums”, Christine is an accidental advocate. After her daughter, Iris, was diagnosed with a rare disease at five, friends, family, and strangers donated so much to a research fund-raising campaign that she had to set up a non-profit to deal with it all.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
MARCH 2, 2021
According to Noxopharm, a recent study shows combining its Veyonda drug and a radiopharmaceutical yields favorable results against prostate cancer.
NY Times
FEBRUARY 28, 2021
The company’s coming trials will also involve pregnant women and people whose immune systems are compromised.
pharmaphorum
MARCH 2, 2021
Clinical trial software facilitates clinical trials from conception to finish. For example protocol management, CRF design , metadata management, and the collection, analysis, and submission of compliant clinical study data to regulatory authorities. The aim is to get quality clinical products to the market faster. Traditionally spreadsheets have been used to record and manage all the various aspects of clinical trials.
Pharma Marketing Network
MARCH 3, 2021
We’ve talked before about how COVID-19 has upended our personal and business lives, and how the pharma industry was able to – impressively – shift gears to meet the challenges the pandemic brought. But what about patients? And what about the disrupted patient journey? What can our industry do to ensure patients maintain continuity of care at a time when good health is imperative?
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
MARCH 1, 2021
A leader from the genetic solutions firm explains how genetic testing and counseling can help trial teams form more beneficial connections with patients.
Pharma Times
MARCH 1, 2021
Latest funding round includes investments from Foresite Capital and F-Prime Capital
pharmaphorum
MARCH 3, 2021
Novavax hopes its COVID-19 vaccine could be filed in the US in the second quarter, following a potential approval from the UK regulator in the coming weeks. The timetable for approval from the FDA depends on whether the regulator accepts data from the company’s trial in the UK, which could set up a potential Emergency Use Authorisation. Following an upbeat Q4 results announcement CEO Stanley Erck told CNBC that discussions with the FDA are ongoing but the hope is that the regulator will accept t
Pharma in Brief
MARCH 1, 2021
On February 24, 2021, Parliament voted down Bill C-213 , which would have enacted the Canada Pharmacare Act. The Private Member’s Bill was first introduced a year ago, re-introduced in September 2020 after Parliament’s prorogation, and defeated at Second Reading. The Canada Pharmacare Act set out a series of criteria and conditions that would have been required before a federal cash contribution could be provided to a province for its public drug insurance plan: public administration; comprehens
Outsourcing Pharma
MARCH 4, 2021
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
Pharma Times
MARCH 4, 2021
Rolling review begins based on lab and clinical studies in adults
pharmaphorum
MARCH 1, 2021
European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups. It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to revive the fortunes of its respiratory diseases franchise.
Drug Patent Watch
MARCH 5, 2021
Annual Drug Patent Expirations for NUPLAZID Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are nineteen…. The post New patent expiration for Acadia Pharms drug NUPLAZID appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MARCH 5, 2021
Today’s guest post comes from Edward Hensley, Co-founder and Chief Commercial Officer at AssistRx. Edward discusses the impact of providing access to drug price transparency and affordability programs to healthcare providers and patients at the point of care. To learn more about AssistRx’s solutions, visit AssistRx.com. Read on for Edward’s insights.
Pharma Times
MARCH 5, 2021
UK’s regulatory authority will fast-track jabs modified to new variants
pharmaphorum
MARCH 4, 2021
UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. The ongoing fight against COVID-19 was a top-line feature of the budget announcement, with an extra £1.65bn to ensure the vaccination roll-out continues to be a success.
Drug Patent Watch
MARCH 5, 2021
Annual Drug Patent Expirations for PHEXXI Phexxi is a drug marketed by Evofem Inc and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent expiration for Evofem Inc drug PHEXXI appeared first on DrugPatentWatch - Make Better Decisions.
Citus Health Specialty Pharmacy
MARCH 3, 2021
Innovative specialty pharmacy provider for hemophiliac and bleeding disorder patients to implement Citus Health’s HIPAA-compliant digital health solution suite to improve patient and staff communications, therapy adherence rates and patient outcomes. NEW YORK (PRWEB) March 04, 2021 Citus Health , a leading digital health solutions provider for the home-based care industry, announced today Fidelis Specialty Pharmacy , a California-based and minority-owned specialty pharmacy serving the blood diso
Pharma Times
MARCH 4, 2021
Collaboration will focus on vaccines for infectious diseases
pharmaphorum
MARCH 5, 2021
The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific mutations making it to market. Alec Mian, CEO at diagnostics firm Curelator, spoke to pharmaphorum’s news editor Richard Staines about the company’s plans to apply a similar paradigm to other diseases such as migraine. . There has been noticeable progress in migraine as a disease area in the last few years, with a new class of drugs coming to market that could help preven
Drug Patent Watch
MARCH 5, 2021
Annual Drug Patent Expirations for NOURESS Nouress is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. There are six patents protecting this drug. Drug patent…. The post New patent for Baxter Hlthcare drug NOURESS appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
MARCH 3, 2021
We’ve talked before about how COVID-19 has upended our personal and business lives, and how the pharma industry was able to – impressively – shift gears to meet the challenges the pandemic brought. But what about patients? And what about the disrupted patient journey? What can our industry do to ensure patients maintain continuity of care at a time when good health is imperative?
Pharma Times
MARCH 1, 2021
Company found to have broken competition law to drive up prices of antidepressant nortriptyline
pharmaphorum
MARCH 5, 2021
In the latest episode of our Health Innovators series, Paul Tunnah speaks to Billy Boyle, co-founder and CEO of Owlstone Medical, one of the UK’s most promising diagnostic startups. The Cambridge, UK-based company is on a mission to save 100,000 lives and $1.5bn in healthcare costs with its breath biopsy platform for early detection of cancer. Owlstone is developing a breath-based analyser that captures Volatile Organic Compounds (VOCs) in breath non-invasively, and analyses them with high sensi
Drug Patent Watch
MARCH 4, 2021
Annual Drug Patent Expirations for ZYCLARA Zyclara is a drug marketed by Bausch and is included in one NDA. It is available from two suppliers. There are six patents protecting…. The post New patent for Bausch drug ZYCLARA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma in Brief
MARCH 2, 2021
Summary. The Federal Court has held that the “related right of action” for infringement of unlisted patents under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ) is not subject to the 45-day limitation period familiar to patentees asserting infringement of listed patents under subsection 6(1). Background. Merck Canada Inc. and Merck Sharp & Dohme Corp.
Pharma Times
MARCH 4, 2021
Final appraisal document said that clinical trial evidence for Poteligeo is ‘very uncertain’
pharmaphorum
MARCH 2, 2021
With COVID-19 forcing a shift towards decentralised trials, two digital health firms – Medable and Seqster – have teamed up to offer ways to also incorporate real-world data into remote study designs. . Decentralised studies reduce or eliminate the need to travel to clinical sites, and the two partners want to go even further by harnessing technologies that can provide additional data in real-time to generate “a more holistic view of patient health,” according to Medable CEO Dr Michelle Longmire
Drug Patent Watch
MARCH 4, 2021
Annual Drug Patent Expirations for INGREZZA Ingrezza is a drug marketed by Neurocrine and is included in one NDA. It is available from one supplier. There are eight patents protecting…. The post New patent for Neurocrine drug INGREZZA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Mirror
MARCH 2, 2021
Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for DAYVIGO in Asia outside of Japan.
Expert insights. Personalized for you.
132 
Let's personalize your content